DE60003182D1 - Extendin-4 konjugate und ihre medizinische verwendung - Google Patents
Extendin-4 konjugate und ihre medizinische verwendungInfo
- Publication number
- DE60003182D1 DE60003182D1 DE60003182T DE60003182T DE60003182D1 DE 60003182 D1 DE60003182 D1 DE 60003182D1 DE 60003182 T DE60003182 T DE 60003182T DE 60003182 T DE60003182 T DE 60003182T DE 60003182 D1 DE60003182 D1 DE 60003182D1
- Authority
- DE
- Germany
- Prior art keywords
- conjugates
- extendin
- medical use
- useful
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000000863 peptide conjugate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14359199P | 1999-07-12 | 1999-07-12 | |
US143591P | 1999-07-12 | ||
EP99610043 | 1999-08-09 | ||
EP99610043A EP1076066A1 (de) | 1999-07-12 | 1999-08-09 | Peptide zur Senkung des Blutglukosespiegels |
PCT/DK2000/000393 WO2001004156A1 (en) | 1999-07-12 | 2000-07-12 | Peptides that lower blood glucose levels |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60003182D1 true DE60003182D1 (de) | 2003-07-10 |
DE60003182T2 DE60003182T2 (de) | 2004-05-06 |
Family
ID=26153727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60003182T Expired - Lifetime DE60003182T2 (de) | 1999-07-12 | 2000-07-12 | Exendin-4 konjugate und ihre medizinische verwendung |
Country Status (20)
Country | Link |
---|---|
US (1) | US20070111940A1 (de) |
EP (4) | EP1076066A1 (de) |
JP (4) | JP4332314B2 (de) |
CN (1) | CN1229390C (de) |
AT (2) | ATE551362T1 (de) |
AU (2) | AU781338B2 (de) |
BE (1) | BE2013C033I2 (de) |
CA (2) | CA2378431C (de) |
CY (2) | CY1113347T1 (de) |
DE (1) | DE60003182T2 (de) |
DK (3) | DK1196444T3 (de) |
ES (3) | ES2529578T3 (de) |
FR (1) | FR13C0021I2 (de) |
HK (2) | HK1058046A1 (de) |
IL (4) | IL147293A0 (de) |
LU (1) | LU92175I2 (de) |
NZ (1) | NZ517012A (de) |
PT (3) | PT2112161E (de) |
SI (2) | SI1329458T1 (de) |
WO (1) | WO2001004156A1 (de) |
Families Citing this family (228)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999046283A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
SE9801571D0 (sv) | 1998-05-05 | 1998-05-05 | Wapharm Ab | Melanokortin-1-receptorselektiva föreningar |
US6444788B1 (en) | 1999-03-15 | 2002-09-03 | Novo Nordisk A/S | Ion exchange chromatography of GLP-1, analogs and derivatives thereof |
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
PT1326630E (pt) | 2000-09-18 | 2008-09-02 | Sanos Bioscience As | Utilização de péptidos glp-2 |
US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
AU3938402A (en) | 2000-12-13 | 2002-06-24 | Lilly Co Eli | Chronic treatment regimen using glucagon-like insulinotropic peptides |
CN1162446C (zh) | 2001-05-10 | 2004-08-18 | 上海华谊生物技术有限公司 | 促胰岛素分泌肽衍生物 |
CN1158304C (zh) * | 2001-05-10 | 2004-07-21 | 上海华谊生物技术有限公司 | 蛙皮抗菌肽衍生物 |
US20030119734A1 (en) | 2001-06-28 | 2003-06-26 | Flink James M. | Stable formulation of modified GLP-1 |
ATE408414T1 (de) | 2001-07-31 | 2008-10-15 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
IL160983A0 (en) | 2001-09-24 | 2004-08-31 | Imp College Innovations Ltd | Use of pyy for preparation of a medicament for modification of feeding behavior |
AU2002351752A1 (en) | 2001-12-29 | 2003-07-30 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
CA2472882A1 (en) | 2002-01-10 | 2003-07-17 | Imperial College Innovations Ltd | Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour |
US7105489B2 (en) * | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
EP1494704A1 (de) * | 2002-04-04 | 2005-01-12 | Novo Nordisk A/S | Verwendung von glp-1-rezeptor-agonisten zur behandlung von kardiovascularen krankheiten |
AU2003243929B2 (en) * | 2002-07-04 | 2009-06-04 | Zp Holding Spv K/S | GLP-1 and methods for treating diabetes |
JP2006501820A (ja) * | 2002-09-06 | 2006-01-19 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 修飾glp−1受容体アゴニストおよびそれらの薬理学的使用法 |
US7273921B2 (en) | 2002-09-25 | 2007-09-25 | Novo Nordisk A/S | Method for producing acylated peptides |
PL377591A1 (pl) * | 2002-10-02 | 2006-02-06 | Zealand Pharma A/S | Stabilizowane związki eksendyny-4 |
EP1559724A4 (de) * | 2002-10-11 | 2006-02-08 | Sanwa Kagaku Kenkyusho Co | Glp-1 derivate und präparate mit transmukosaler absorption daraus |
US6818721B2 (en) | 2002-12-02 | 2004-11-16 | Rpo Pty Ltd. | Process for producing polysiloxanes and use of the same |
EP1688148A1 (de) * | 2002-12-03 | 2006-08-09 | Novo Nordisk A/S | Behandlung mit Kombinationspräparaten aus Exendin-4 und Thiazolidindionen |
AU2003283216A1 (en) * | 2002-12-03 | 2004-06-23 | Novo Nordisk A/S | Combination treatment using exendin-4 and thiazolidinediones |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
WO2004078777A2 (en) * | 2003-03-04 | 2004-09-16 | Biorexis Pharmaceutical Corporation | Dipeptidyl-peptidase protected proteins |
DE10314610A1 (de) | 2003-04-01 | 2004-11-04 | Aventis Pharma Deutschland Gmbh | Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung |
ES2425221T3 (es) | 2003-05-30 | 2013-10-14 | Amylin Pharmaceuticals, Llc | Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas |
US7008957B2 (en) | 2003-07-25 | 2006-03-07 | Sanofi-Aventis Deutschland Gmbh | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
US7094800B2 (en) | 2003-07-25 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Cyanopyrrolidides, process for their preparation and their use as medicaments |
US7094794B2 (en) | 2003-07-28 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use |
DE10335092B3 (de) | 2003-08-01 | 2005-02-03 | Aventis Pharma Deutschland Gmbh | Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung |
TW200522976A (en) | 2003-09-19 | 2005-07-16 | Novo Nordisk As | Novel plasma protein affinity tags |
CN101380476A (zh) * | 2003-09-19 | 2009-03-11 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
SI2932981T1 (sl) * | 2003-09-19 | 2021-11-30 | Novo Nordisk A/S | Albumin-vezavni derivati GLP-1 |
US20060287221A1 (en) | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
WO2005046716A1 (en) * | 2003-11-13 | 2005-05-26 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia |
CN104826116A (zh) | 2003-11-20 | 2015-08-12 | 诺沃挪第克公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
JP4865565B2 (ja) | 2003-12-09 | 2012-02-01 | ノヴォ ノルディスク アー/エス | Glp−1アゴニストを用いた食物選択の制御 |
EP1701731A4 (de) * | 2003-12-12 | 2009-08-05 | Einstein Coll Med | Glp-1 (9-36) verfahren und zusammensetzungen |
WO2005058954A1 (en) | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 compounds |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
EP2422807A3 (de) | 2004-02-11 | 2012-05-30 | Amylin Pharmaceuticals Inc. | Hybridpolypeptide mit auswahlbaren Eigenschaften |
CN1318587C (zh) * | 2004-04-30 | 2007-05-30 | 成都芝田生物工程有限公司 | 酰胺化Exendin-4多肽的重组制备方法 |
CN1950078A (zh) | 2004-06-11 | 2007-04-18 | 诺和诺德公司 | 使用glp-1激动剂抵抗药物诱发的肥胖 |
DE102004043153B4 (de) * | 2004-09-03 | 2013-11-21 | Philipps-Universität Marburg | Erfindung betreffend GLP-1 und Exendin |
AU2012202855B2 (en) * | 2004-09-03 | 2015-02-26 | Philipps-Universitat Marburg | GLP-1 and exendin related invention |
JP5107713B2 (ja) | 2004-10-07 | 2012-12-26 | ノヴォ ノルディスク アー/エス | 遅延性のエキセンディン−4化合物 |
JP2008515856A (ja) | 2004-10-07 | 2008-05-15 | ノボ ノルディスク アクティーゼルスカブ | 遅延性glp−1化合物 |
EP1814581B1 (de) * | 2004-11-12 | 2016-03-16 | Novo Nordisk A/S | Stabile peptidformulierungen enthaltend ein acyliertes glp-1 analogon und ein basales insulin |
DE102004058306A1 (de) * | 2004-12-01 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden |
US8716221B2 (en) | 2005-01-14 | 2014-05-06 | Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. | Modified exendins and uses thereof |
JP4785206B2 (ja) * | 2005-01-14 | 2011-10-05 | ウクスィ・グランドチャンプ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド | 修飾されたエキセンディン(Exendins)及びその使用 |
KR20070115947A (ko) | 2005-02-11 | 2007-12-06 | 아밀린 파마슈티칼스, 인크. | 선택가능한 특성들을 가지는 gip 유사체 및 하이브리드폴리펩타이드 |
US20090286723A1 (en) | 2005-02-11 | 2009-11-19 | Amylin Pharmaceuticals, Inc. | Hybrid Polypeptides with Selectable Properties |
JP2008531730A (ja) | 2005-03-04 | 2008-08-14 | キュアーディーエム、インク. | I型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物 |
EP1863521B1 (de) * | 2005-03-18 | 2014-05-07 | Novo Nordisk A/S | Erweiterte glp-1-verbindungen |
WO2006097535A2 (en) * | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Peptide agonists of the glucagon family with secretin like activity |
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
EP2295452A1 (de) | 2005-05-04 | 2011-03-16 | Zealand Pharma A/S | Glucagon-like peptide-2 (GLP-2) Analoga |
EA013821B1 (ru) | 2005-05-25 | 2010-08-30 | Кьюрдм, Инк. | Проостровковые пептиды человека, их производные и аналоги и способы их применения |
BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
NZ568421A (en) | 2005-08-26 | 2010-01-29 | Action Pharma As | Therapeutically active alpha-MSH analogues |
DE102006031955A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende |
DE102006031962A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes Insulin Glargin |
ATE524493T1 (de) | 2006-07-24 | 2011-09-15 | Biorexis Pharmaceutical Corp | Exendin-fusionsproteine |
EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
AU2007293885A1 (en) | 2006-09-07 | 2008-03-13 | Takeda Gmbh | Combination treatment for diabetes mellitus |
KR101527233B1 (ko) | 2006-11-08 | 2015-06-08 | 질랜드 파마 에이/에스 | 선택적인 글루카곤 유사 펩티드-2(glp-2) 유사체 |
JP2010043001A (ja) * | 2006-11-09 | 2010-02-25 | Sanwa Kagaku Kenkyusho Co Ltd | Glp−1誘導体とその用途 |
WO2008064306A2 (en) | 2006-11-22 | 2008-05-29 | Curedm, Inc. | Methods and compositions relating to islet cell neogenesis |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
RU2413528C2 (ru) | 2007-01-18 | 2011-03-10 | Открытое Акционерное Общество "Валента Фармацевтика" | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения |
DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2008098693A2 (en) * | 2007-02-16 | 2008-08-21 | Bayer Healthcare Ag | Convergent synthesis of glp-1 |
WO2008149345A2 (en) | 2007-06-04 | 2008-12-11 | Ben-Gurion University Of The Negev Research And Development Authority | Tri-aryl compounds and compositions comprising the same |
EP2158214B1 (de) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagonanaloga |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
NZ599756A (en) | 2007-08-30 | 2013-09-27 | Curedm Group Holdings Llc | Compositions and methods of using proislet peptides and analogs thereof |
CN101868476B (zh) | 2007-09-05 | 2015-02-25 | 诺沃-诺迪斯克有限公司 | 胰高血糖素样肽-1衍生物及其制药用途 |
WO2009030774A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Truncated glp-1 derivatives and their therapeutical use |
CA2703113A1 (en) | 2007-10-27 | 2009-04-30 | F. Hoffmann-La Roche Ag | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
BRPI0820535B8 (pt) | 2007-11-16 | 2021-05-25 | Novo Nordisk As | composições farmacêuticas contendo insulina e um peptídeo insulinotrópico |
DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
DE102008025008A1 (de) | 2008-05-24 | 2009-11-26 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
CN101970476B (zh) | 2008-01-09 | 2014-08-27 | 塞诺菲-安万特德国有限公司 | 具有超延迟时效特征的胰岛素衍生物 |
DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
EP2229407B1 (de) | 2008-01-09 | 2016-11-16 | Sanofi-Aventis Deutschland GmbH | Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil |
DE102008025007A1 (de) | 2008-05-24 | 2009-11-26 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
CA2729296A1 (en) * | 2008-06-17 | 2010-01-28 | Richard D. Dimarchi | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
EP2926825A1 (de) | 2008-06-27 | 2015-10-07 | Duke University | Therapeutika mit elastinähnlichen peptiden |
US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
US8865868B2 (en) | 2008-08-06 | 2014-10-21 | Novo Nordisk Healthcare Ag | Conjugated proteins with prolonged in vivo efficacy |
DE102009038210A1 (de) | 2009-08-20 | 2011-03-03 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
DE102008051834A1 (de) | 2008-10-17 | 2010-04-22 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
RS59913B1 (sr) | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
DE102008053048A1 (de) | 2008-10-24 | 2010-04-29 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
US8889618B2 (en) | 2008-11-07 | 2014-11-18 | The General Hospital Corporation | C-terminal fragments of glucagon-like peptide-1 (GLP-1) |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
PT2373681T (pt) | 2008-12-10 | 2017-04-11 | Glaxosmithkline Llc | Composições farmacêuticas de albiglutida |
AU2008365556A1 (en) | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
ES2439499T3 (es) | 2008-12-15 | 2014-01-23 | Zealand Pharma A/S | Análogos de glucagón |
MX2011006315A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
CA2747109A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
AU2010207725B2 (en) | 2009-01-22 | 2015-06-11 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
WO2011003823A1 (de) * | 2009-07-06 | 2011-01-13 | Sanofi-Aventis Deutschland Gmbh | Langsamwirkende insulinzubereitungen |
MY159865A (en) * | 2009-07-06 | 2017-02-15 | Sanofi Aventis Deutschland | Aqueous insulin preparations containing methionine |
EA022816B1 (ru) | 2009-07-13 | 2016-03-31 | Зилэнд Фарма А/С | Ацилированные аналоги глюкагона |
CN101987868B (zh) * | 2009-07-30 | 2013-09-04 | 江苏豪森医药集团有限公司 | Glp-1类似物的衍生物或其可药用盐和用途 |
JP6086528B2 (ja) | 2009-08-06 | 2017-03-01 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 長期のインビボ有効性を有する成長ホルモン |
RU2012111354A (ru) | 2009-08-26 | 2013-10-10 | Санофи | Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование |
EP2491054A2 (de) | 2009-10-22 | 2012-08-29 | Cadila Healthcare Limited | Auf kurzkettigen peptidomimetika basierende oral aktive glp-1-agonisten und glucagonrezeptor-antagonisten |
AU2009238272B2 (en) * | 2009-11-13 | 2014-05-08 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
SI2324853T1 (sl) | 2009-11-13 | 2015-12-31 | Sanofi-Aventis Deutschland Gmbh | Liksisenatid kot dodatek metforminu pri zdravljenju sladkorne bolezni tipa 2 |
ES2398012T5 (es) | 2009-11-13 | 2020-02-26 | Sanofi Aventis Deutschland | Lixisenatide como terapia complementaria a insulina glargina y metformina para tratar diabetes de tipo 2 |
DE102010011919A1 (de) | 2010-03-18 | 2011-09-22 | Sanofi-Aventis Deutschland Gmbh | Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin |
JP2011105609A (ja) * | 2009-11-13 | 2011-06-02 | Sanofi-Aventis Deutschland Gmbh | メトホルミンへの付加療法を含む2型糖尿病の治療方法 |
ES2534191T3 (es) | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
KR101337322B1 (ko) | 2009-11-13 | 2013-12-06 | 사노피-아벤티스 도이칠란트 게엠베하 | Glp-1 효능제 및 메티오닌을 포함하는 약제학적 조성물 |
EP2525809B1 (de) | 2010-01-20 | 2016-08-03 | Zealand Pharma A/S | Glukagon-glp1 doppelagonisten zur behandlung von herzkrankheiten |
BR112012018162A2 (pt) | 2010-01-22 | 2017-10-03 | Novo Nordisk Healthcare Ag | Compostos de hormônio do crescimento estáveis |
BR112012018116B1 (pt) | 2010-01-22 | 2022-06-21 | Novo Nordisk Health Care Ag | Conjugados de hormônio do crescimento com eficácia in vivo prolongada |
US9422330B2 (en) | 2010-03-01 | 2016-08-23 | Novo Nordisk A/S | Preparative RP-HPLC method for purifying peptides |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2555791B1 (de) | 2010-04-09 | 2017-11-01 | Sinai Health System | Verfahren zur behandlung von erkrankungen des magen-darm-trakts mittels eines glp-1-agonisten |
DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
KR20130098873A (ko) | 2010-04-27 | 2013-09-05 | 질랜드 파마 에이/에스 | Glp-1 수용체 작용제 및 가스트린의 펩타이드 접합체 및 그의 용도 |
US8691763B2 (en) | 2010-05-04 | 2014-04-08 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
EP2389945A1 (de) | 2010-05-28 | 2011-11-30 | Sanofi-Aventis Deutschland GmbH | Pharmazeutische Zusammensetzung mit AVE0010 und Insulin glargin |
CN101891823B (zh) * | 2010-06-11 | 2012-10-03 | 北京东方百泰生物科技有限公司 | 一种Exendin-4及其类似物融合蛋白 |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
SG186764A1 (en) | 2010-06-24 | 2013-02-28 | Zealand Pharma As | Glucagon analogues |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
BR112013004756B1 (pt) | 2010-08-30 | 2020-04-28 | Sanofi Aventis Deutschland | uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2 |
WO2012061466A2 (en) | 2010-11-02 | 2012-05-10 | The General Hospital Corporation | Methods for treating steatotic disease |
PL2651398T3 (pl) | 2010-12-16 | 2018-05-30 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego |
WO2012104342A1 (en) | 2011-02-02 | 2012-08-09 | Sanofi-Aventis Deutschland Gmbh | Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US20120277147A1 (en) | 2011-03-29 | 2012-11-01 | Sanofi-Aventis Deutschland Gmbh | Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
EP3225631B1 (de) | 2011-04-12 | 2019-01-09 | Novo Nordisk A/S | Zweifach acylierte glp-1-derivate |
US20130040878A1 (en) | 2011-05-13 | 2013-02-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in the treatment of diabetes type 2 patients |
US8735349B2 (en) | 2011-05-13 | 2014-05-27 | Sanofi-Aventis Deutschland Gmbh | Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
JP6442284B2 (ja) | 2011-05-13 | 2018-12-19 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病の処置のためのリキシセナチド及びメトホルミン |
EP2729157B1 (de) | 2011-07-06 | 2019-01-16 | The General Hospital Corporation | Ein pentapeptid aus dem c-terminus des glucagon-like peptids-1 (glp-1) zur verwendung in der behandlung |
PL2750699T3 (pl) | 2011-08-29 | 2015-12-31 | Sanofi Aventis Deutschland | Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2 |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (de) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren |
EP2760862B1 (de) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren |
EP2763691A1 (de) | 2011-10-04 | 2014-08-13 | Sanofi-Aventis Deutschland GmbH | Glp-1-agonist zur verwendung bei der behandlung von stenose und/oder verstopfungen im pankreasgangsystem |
EP2763690B1 (de) | 2011-10-04 | 2015-11-25 | Sanofi-Aventis Deutschland GmbH | Lixisenatide zur behandlung von stenosen oder/und obstruktionen im pankreasgangsystem |
CN107693783A (zh) | 2011-10-28 | 2018-02-16 | 赛诺菲-安万特德国有限公司 | 2型糖尿病的治疗方案 |
AR088636A1 (es) | 2011-11-03 | 2014-06-25 | Zealand Pharma As | Conjugados peptidicos de un agonista del receptor de glp-1 y gastrina |
CN103087174B (zh) * | 2011-11-03 | 2015-11-18 | 华东师范大学 | 一种glp-1衍生物dlg3312及其固相化学合成方法 |
JP2015500823A (ja) | 2011-12-09 | 2015-01-08 | ノヴォ ノルディスク アー/エス | Glp−1アゴニスト |
EP2793931A2 (de) | 2011-12-23 | 2014-10-29 | Zealand Pharma A/S | Glucagon-analoga |
ES2952874T3 (es) | 2012-03-22 | 2023-11-06 | Novo Nordisk As | Composiciones de péptidos GLP-1 y preparación de estas |
HUE042757T2 (hu) | 2012-03-22 | 2019-07-29 | Novo Nordisk As | Szállító szert tartalmazó készítmények és elõállításuk |
EP2844670B1 (de) | 2012-05-03 | 2017-12-06 | Zealand Pharma A/S | Glucagon-artige peptid-2-analoga (glp-2-)analoga |
SG11201407137PA (en) | 2012-05-03 | 2014-11-27 | Zealand Pharma As | Gip-glp-1 dual agonist compounds and methods |
JP6517690B2 (ja) | 2012-06-20 | 2019-05-22 | ノヴォ ノルディスク アー/エス | ペプチド及び送達剤を含む錠剤製剤 |
CN104662038B (zh) | 2012-07-23 | 2018-11-06 | 西兰制药公司 | 胰高血糖素类似物 |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
CN105142621A (zh) | 2012-10-24 | 2015-12-09 | 国家健康科学研究所 | 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂 |
WO2014077575A1 (ko) * | 2012-11-13 | 2014-05-22 | 다인바이오 주식회사 | 덱에이 효소반응으로 조제한 항비만 및 항당뇨 효능을 갖는 한천 유래 네오아가로올리고당 복합 조성물 |
KR20140088837A (ko) * | 2013-01-03 | 2014-07-11 | 한미약품 주식회사 | N-말단 전하가 변형된 인슐린 분비 펩티드 유도체 |
TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
EP3517122A1 (de) | 2013-04-03 | 2019-07-31 | Sanofi | Behandlung von diabetes mellitus durch langzeitwirkende formulierungen von insulinen |
US11045523B2 (en) | 2013-04-05 | 2021-06-29 | Novo Nordisk Healthcare Ag | Formulation of growth hormone albumin-binder conjugate |
AR096789A1 (es) | 2013-07-04 | 2016-02-03 | Novo Nordisk As | Derivados de péptidos similares a glp-1 y usos de los mismos |
GB201315335D0 (en) * | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
US9988429B2 (en) * | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
MY176022A (en) | 2013-10-17 | 2020-07-21 | Boehringer Ingelheim Int | Acylated glucagon analogues |
US10111880B2 (en) | 2013-11-05 | 2018-10-30 | Ben-Gurion University Of The Negev Research And Development Authority | Compounds for the treatment of diabetes and disease complications arising from same |
KR102310389B1 (ko) | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | Gip-glp-1 이원 효능제 화합물 및 방법 |
TR201902516T4 (tr) | 2013-11-06 | 2019-03-21 | Zealand Pharma As | Glukagon-glp-1-gıp üçlü agonist bileşikleri. |
CN103613657B (zh) * | 2013-11-28 | 2016-01-13 | 孙玉琨 | 缩短肽链的Exendin4及其基因工程应用 |
KR20160104726A (ko) | 2014-01-09 | 2016-09-05 | 사노피 | 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형 |
SG11201604710XA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
KR20160101195A (ko) | 2014-01-09 | 2016-08-24 | 사노피 | 인슐린 아스파트의 안정화된 약제학적 제형 |
KR101768446B1 (ko) * | 2014-03-21 | 2017-08-17 | 애니젠 주식회사 | 신규한 엑세나타이드 유사체 및 그의 용도 |
DK3212218T3 (da) | 2014-10-29 | 2021-08-30 | Zealand Pharma As | GIP-agonistforbindelser og fremgangsmåder |
HRP20230470T1 (hr) | 2014-12-12 | 2023-07-21 | Sanofi-Aventis Deutschland Gmbh | Formulacija fiksnog omjera inzulin glargin/liksisenatid |
US20160235818A1 (en) | 2015-01-16 | 2016-08-18 | Sanofi-Aventis Deutschland Gmbh | Treatment of Pediatric Type 2 Diabetes Mellitus Patients |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
EP3273981B1 (de) | 2015-03-24 | 2020-04-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung von diabetes |
CN107636010B (zh) | 2015-04-16 | 2021-10-01 | 西兰制药公司 | 酰化胰高血糖素类似物 |
CA3043151A1 (en) | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
IL271245B2 (en) | 2017-06-16 | 2023-10-01 | Zealand Pharma As | Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2 |
FR3082426A1 (fr) | 2018-06-14 | 2019-12-20 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale |
ES2917893T3 (es) | 2017-07-27 | 2022-07-12 | Adocia | Composiciones en forma de una solución acuosa inyectable que comprenden al menos insulina humana A21G y un supresor de glucagón con acción prandial |
CN111050750A (zh) | 2017-08-24 | 2020-04-21 | 诺沃挪第克公司 | Glp-1组合物及其用途 |
MX2020007598A (es) | 2018-02-02 | 2020-09-03 | Novo Nordisk As | Composiciones solidas que comprenden un agonista del peptido similar al glucagon tipo 1 (glp-1), una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante. |
US11560402B2 (en) | 2018-04-10 | 2023-01-24 | Sanofi-Aventis Deutschland Gmbh | Method for cleavage of solid phase-bound peptides from the solid phase |
EP3774838B1 (de) | 2018-04-10 | 2022-08-10 | Sanofi-Aventis Deutschland GmbH | Lixisenatidsynthese mit verkappung |
FR3083700B1 (fr) | 2018-07-13 | 2021-03-12 | Adocia | Formulation thermostable d'insuline humaine a21g |
EP3628682A1 (de) | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulierungen von analoga des glucagon-like-peptid-2 (glp-2) |
EP3628683A1 (de) | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulierungen von analoga des glucagon-like-peptid-2 (glp-2) |
TWI799680B (zh) * | 2019-01-29 | 2023-04-21 | 美商美國禮來大藥廠 | 製備gip/glp1雙重促效劑之方法 |
CN109721653B (zh) * | 2019-03-05 | 2023-02-03 | 嘉兴学院 | 一种胰高血糖素样肽-1片段类似物及其应用 |
US20210093698A1 (en) | 2019-09-13 | 2021-04-01 | Sanofi | Treatment of type 2 diabetes mellitus |
EP3858373A1 (de) | 2020-01-31 | 2021-08-04 | Adocia | Zusammensetzungen mit mindestens einem amylin-rezeptor-agonisten und einem glp-1-rezeptor-agonisten |
KR20220143036A (ko) | 2020-02-18 | 2022-10-24 | 노보 노르디스크 에이/에스 | 약학적 제형 |
EP3915572A1 (de) | 2020-05-29 | 2021-12-01 | Adocia | Pharmazeutische zusammensetzung in form einer injizierbaren wässrigen lösung mit mindestens einem schnell wirkenden insulinanalogon und einem glucagon-suppressor mit prandialer wirkung |
EP3915571A1 (de) | 2020-05-29 | 2021-12-01 | Adocia | Pharmazeutische zusammensetzung in form einer injizierbaren wässrigen lösung mit mindestens einem schnell wirkenden insulinanalogon und einem glucagon-suppressor mit prandialer wirkung |
AU2021397877A1 (en) * | 2020-12-11 | 2023-07-06 | Ip2Ipo Innovations Limited | Novel compounds |
EP4129324A1 (de) | 2021-08-02 | 2023-02-08 | Adocia | Zusammensetzungen mit mindestens einem amylin-rezeptor-agonisten und einem glp-1-rezeptor-agonisten |
KR20240055083A (ko) | 2021-09-10 | 2024-04-26 | 질랜드 파마 에이/에스 | 글루카곤 유사 펩티드-2(glp-2) 아날로그를 포함하는 조성물을 제제화하는 방법 |
WO2023118416A1 (en) | 2021-12-23 | 2023-06-29 | Zealand Pharma A/S | Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues |
WO2024068848A1 (en) | 2022-09-28 | 2024-04-04 | Zealand Pharma A/S | Methods for treating obesity |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4288627A (en) | 1980-02-12 | 1981-09-08 | Phillips Petroleum Company | Oxidation of thiols employing cobalt molybdate/triethylamine catalyst |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
AU639570B2 (en) | 1990-05-09 | 1993-07-29 | Novozymes A/S | A cellulase preparation comprising an endoglucanase enzyme |
DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
ATE417622T1 (de) * | 1996-08-08 | 2009-01-15 | Amylin Pharmaceuticals Inc | Regulation gastrointestinaler beweglichkeit |
US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
ATE356830T1 (de) * | 1996-08-30 | 2007-04-15 | Novo Nordisk As | Glp-1 derivate |
AU724326B2 (en) * | 1996-09-09 | 2000-09-14 | Zealand Pharmaceuticals A/S | Peptide prodrugs containing an alpha-hydroxyacid linker |
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
WO1998022577A1 (en) * | 1996-11-15 | 1998-05-28 | Maria Grazia Masucci | Fusion proteins having increased half-lives |
WO1998030231A1 (en) * | 1997-01-07 | 1998-07-16 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
EP0981611A1 (de) | 1997-02-05 | 2000-03-01 | 1149336 Ontario Inc. | Für ProeXENDIN KODIERENDE POLYNUKLEOTIDE, Verfahren UND ANWENDUNGEN derselben |
US5846937A (en) | 1997-03-03 | 1998-12-08 | 1149336 Ontario Inc. | Method of using exendin and GLP-1 to affect the central nervous system |
EP1019077B2 (de) * | 1997-08-08 | 2010-12-22 | Amylin Pharmaceuticals, Inc. | Neue exendinagonist verbindungen |
EP1066314B1 (de) * | 1997-11-14 | 2007-12-26 | Amylin Pharmaceuticals, Inc. | Neuartige exendin agonisten |
BR9814189A (pt) * | 1997-11-14 | 2000-10-03 | Amylin Pharmaceuticals Inc | "compostos agonistas da exendina" |
AU759058C (en) | 1998-02-13 | 2005-09-15 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
EP1062240B1 (de) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | N-terminal veränderte glp-1 abkömmlinge |
WO1999043708A1 (en) * | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
WO1999046283A1 (en) * | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
US6451974B1 (en) * | 1999-03-17 | 2002-09-17 | Novo Nordisk A/S | Method of acylating peptides and novel acylating agents |
BR0010705A (pt) * | 1999-04-30 | 2002-02-05 | Amylin Pharmaceuticals Inc | Exendinas modificadas e agonistas da exendina |
US6528486B1 (en) * | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
AU2003243929B2 (en) * | 2002-07-04 | 2009-06-04 | Zp Holding Spv K/S | GLP-1 and methods for treating diabetes |
PL377591A1 (pl) * | 2002-10-02 | 2006-02-06 | Zealand Pharma A/S | Stabilizowane związki eksendyny-4 |
-
1999
- 1999-08-09 EP EP99610043A patent/EP1076066A1/de not_active Withdrawn
-
2000
- 2000-07-12 CA CA2378431A patent/CA2378431C/en not_active Expired - Lifetime
- 2000-07-12 DK DK00945656T patent/DK1196444T3/da active
- 2000-07-12 SI SI200031068T patent/SI1329458T1/sl unknown
- 2000-07-12 PT PT90029372T patent/PT2112161E/pt unknown
- 2000-07-12 PT PT00945656T patent/PT1196444E/pt unknown
- 2000-07-12 ES ES09002937.2T patent/ES2529578T3/es not_active Expired - Lifetime
- 2000-07-12 NZ NZ517012A patent/NZ517012A/xx not_active IP Right Cessation
- 2000-07-12 AU AU59660/00A patent/AU781338B2/en active Active
- 2000-07-12 DK DK09002937.2T patent/DK2112161T3/en active
- 2000-07-12 IL IL14729300A patent/IL147293A0/xx active IP Right Grant
- 2000-07-12 EP EP03005786A patent/EP1329458B9/de not_active Expired - Lifetime
- 2000-07-12 CA CA002680437A patent/CA2680437A1/en not_active Abandoned
- 2000-07-12 ES ES00945656T patent/ES2200892T3/es not_active Expired - Lifetime
- 2000-07-12 AT AT03005786T patent/ATE551362T1/de active
- 2000-07-12 JP JP2001509765A patent/JP4332314B2/ja not_active Expired - Lifetime
- 2000-07-12 WO PCT/DK2000/000393 patent/WO2001004156A1/en active Application Filing
- 2000-07-12 DK DK03005786.3T patent/DK1329458T5/da active
- 2000-07-12 EP EP00945656A patent/EP1196444B8/de not_active Expired - Lifetime
- 2000-07-12 AT AT00945656T patent/ATE242267T1/de active
- 2000-07-12 PT PT03005786T patent/PT1329458E/pt unknown
- 2000-07-12 CN CNB008102082A patent/CN1229390C/zh not_active Expired - Lifetime
- 2000-07-12 DE DE60003182T patent/DE60003182T2/de not_active Expired - Lifetime
- 2000-07-12 EP EP09002937.2A patent/EP2112161B1/de not_active Expired - Lifetime
- 2000-07-12 ES ES03005786T patent/ES2384963T3/es not_active Expired - Lifetime
- 2000-07-12 SI SI200031086T patent/SI2112161T1/sl unknown
-
2001
- 2001-12-25 IL IL147293A patent/IL147293A/en active Protection Beyond IP Right Term
-
2004
- 2004-01-03 HK HK04100046.0A patent/HK1058046A1/xx unknown
- 2004-01-03 HK HK10103568.4A patent/HK1135119A1/xx unknown
-
2005
- 2005-08-19 AU AU2005203735A patent/AU2005203735B2/en not_active Expired
-
2006
- 2006-09-05 US US11/515,812 patent/US20070111940A1/en not_active Abandoned
- 2006-09-07 JP JP2006243389A patent/JP5414144B2/ja not_active Expired - Lifetime
-
2007
- 2007-09-06 IL IL185763A patent/IL185763A/en active IP Right Grant
-
2010
- 2010-06-17 IL IL206445A patent/IL206445A/en active IP Right Grant
- 2010-12-24 JP JP2010286968A patent/JP5553742B2/ja not_active Expired - Lifetime
-
2012
- 2012-06-26 CY CY20121100561T patent/CY1113347T1/el unknown
-
2013
- 2013-03-27 LU LU92175C patent/LU92175I2/fr unknown
- 2013-04-02 FR FR13C0021C patent/FR13C0021I2/fr active Active
- 2013-05-29 BE BE2013C033C patent/BE2013C033I2/fr unknown
- 2013-07-11 CY CY2013032C patent/CY2013032I1/el unknown
-
2014
- 2014-04-08 JP JP2014079124A patent/JP2014169296A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60003182D1 (de) | Extendin-4 konjugate und ihre medizinische verwendung | |
DE60223841D1 (de) | Medizinische verwendung von gsk3-hemmenden oxindolderivaten | |
TR200103469T2 (tr) | Amiloidojenik hastalığının önlenmesi ve tedavisi | |
ATE527375T1 (de) | Diagnose und behandlung von brustkrebs mit scn5a | |
TR200101867T2 (tr) | CCR5 modülatörleri olarak piperidinler | |
DE60003863D1 (de) | Dioxocyclopentylhydroxamsäure | |
TR200101793T2 (tr) | CCR5 modülatörleri olarak azabisikloalkanlar | |
ATE420097T1 (de) | Substituierte sapogenine und ihre verwendung | |
DE69939068D1 (de) | Entfernbare implantierbare medizinische leitung | |
BR0201862A (pt) | Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos | |
IS6879A (is) | Neublastín sem tengt er fjölliðu og aðferðir við notkun þess | |
DE60141074D1 (de) | Derivate von kettenverzweigten lipophilen molekülen und deren verwendung | |
BR0014372A (pt) | Derivados de 5-hidroxissapogenina com atividade antidemência | |
CY1111900T1 (el) | Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα ν-μεθυλ-d-ασπαρτικων (nmda) | |
ATE428438T1 (de) | Tcf-ii enthaltende medizinische zusammensetzung | |
ID25478A (id) | Agonis 5-ht1f | |
PT1606233E (pt) | Derivados de esteres lipidicos de nucleotidos | |
ATE363072T1 (de) | Monoklonaler antikörper gegen mxa und mxb | |
CY1106882T1 (el) | Τροποποιηση βητακυτταρουλινης | |
CY1115962T1 (el) | Πεπτιδια που μειωνουν τα επιπεδα της γλυκοζης στο αιμα | |
CY1115252T1 (el) | Αντισωμα εναντιον cd22 για την θεραπευτικη αγωγη ογκου αιματοποιητικης προελευσης | |
ATE295117T1 (de) | Medizinische bandelektrode |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
R065 | Request for grant of supplementary protection certificate validly filed |
Free format text: PRODUCT NAME: LIXISENATID; REGISTRATION NO/DATE: EU/1/12/811/001-005 20130201 Spc suppl protection certif: 122013000036 Filing date: 20130419 Expiry date: 20200713 Effective date: 20130425 |
|
R067 | Examining division decision granting supplementary protection certificate |
Free format text: PRODUCT NAME: LIXISENATID; REGISTRATION NO/DATE: EU/1/12/811/001-005 20130201 Spc suppl protection certif: 122013000036 Filing date: 20130419 Expiry date: 20200713 Extension date: 20250712 |
|
R069 | Supplementary protection certificate granted |
Free format text: PRODUCT NAME: LIXISENATID; REGISTRATION NO/DATE: EU/1/12/811/001-005 20130201 Spc suppl protection certif: 122013000036 Filing date: 20130419 Expiry date: 20200713 Extension date: 20250712 |